The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kaprin A.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia;
Peoples’ Friendship University of Russia

Zaitsev A.M.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Rerberg A.G.

Herzen Moscow Oncology Research Institute — Branch Campus of the National Medical Radiology Research Center

Fedenko A.A.

Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Datsenko P.V.

National Research Medical Center of Radiology

Kirsanova O.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Superselective intra-arterial administration of bevacizumab with blood-brain barrier disruption in patients with recurrent malignant gliomas: case report and literature review

Authors:

Kaprin A.D., Zaitsev A.M., Rerberg A.G., Fedenko A.A., Datsenko P.V., Kirsanova O.N.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2021;85(5): 64‑70

DOI: 10.17116/neiro20218505164

Read: 5163 times

Download PDF (RU)
Download PDF
Contact the author
Table of contents

SUPERSELECTIVE INTRA-ARTERIAL ADMINISTRATION OF BEVACIZUMAB WITH BLOOD-BRAIN BARRIER DISRUPTION IN PATIENTS WITH RECURRENT MALIGNANT GLIOMAS: CASE REPORT AND LITERATURE REVIEW
SUPERSELECTIVE INTRA-ARTERIAL ADMINISTRATION OF BEVACIZUMAB WITH BLOOD-BRAIN BARRIER DISRUPTION IN PATIENTS WITH RECURRENT MALIGNANT GLIOMAS: CASE REPORT AND LITERATURE REVIEW

To cite this article:

Kaprin AD, Zaitsev AM, Rerberg AG, Fedenko AA, Datsenko PV, Kirsanova ON. Superselective intra-arterial administration of bevacizumab with blood-brain barrier disruption in patients with recurrent malignant gliomas: case report and literature review. Burdenko's Journal of Neurosurgery. 2021;85(5):64‑70. (In Russ., In Engl.)
https://doi.org/10.17116/neiro20218505164

Подписка 2025 Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко (Burdenko's Journal of Neurosurgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A Novel Rat Glioblastoma 101/8 Model: A Comparative PET-CT Study with C6 Rat model. Burdenko's Journal of Neurosurgery. 2024;(6):54-62
Anti­gen rece­ptors in the deve­lopment of CAR-T cells for glioblastoma immu­notherapy. P.A. Herzen Journal of Onco­logy. 2024;(6):91-95
The choice of radiotherapy dose fractionation regi­men for grade 4 gliomas depe­nding on the status of MGMT. P.A. Herzen Journal of Onco­logy. 2025;(1):13-18
Radiation therapy with focal dose esca­lation in the treatment of glioblastoma. P.A. Herzen Journal of Onco­logy. 2025;(2):64-69
Effi­cacy of chemoimmunotargeted therapy in patients with adva­nced non-small cell lung cancer in real clinical practice. P.A. Herzen Journal of Onco­logy. 2025;(3):63-70
Glymphatic system in health and disease: a narrative review. Burdenko's Journal of Neurosurgery. 2025;(4):112-118
TERTp muta­tion screening using digi­tal droplet PCR of collection of 52 paired DNA samples from blood plasma and tumor tissue in patients with glioblastoma. Burdenko's Journal of Neurosurgery. 2025;(5):87-95
Fluorescence navi­gation and endo­scopic assi­stance in surgery for brain glioblastomas. Burdenko's Journal of Neurosurgery. 2025;(6):28-37
Abstract:

Glioblastoma multiforme is characterized by persistent recurrent course despite surgical, radio- and chemotherapeutic treatment. The outcomes of superselective intra-arterial administration of bevacizumab with blood-brain barrier disruption in patients with recurrent glioblastoma have been published. The authors reported significant increase in overall survival (up to 2.5 years). We report treatment of recurrent glioblastoma in a young patient with progressive course of disease despite 4 previous neurosurgical interventions, radiotherapy and first-line chemotherapy. Superselective intra-arterial administration of bevacizumab with blood-brain barrier disruption made it possible to achieve clinical response and improve neurological status.

Keywords:

glioblastoma
bevacizumab
blood-barrier disruption
superselective intra-arterial infusion

Authors:

Kaprin A.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia;
Peoples’ Friendship University of Russia

Zaitsev A.M.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Rerberg A.G.

Herzen Moscow Oncology Research Institute — Branch Campus of the National Medical Radiology Research Center

Fedenko A.A.

Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Datsenko P.V.

National Research Medical Center of Radiology

Kirsanova O.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Received:

31.01.2021

Accepted:

05.08.2021

Close metadata

References:

  1. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100(1):44-52.  https://doi.org/10.1002/cncr.11859
  2. Neuwelt EA, Minna J, Frenkel E, Barnett PA, McCormick CI. Osmotic blood-brain barrier opening to IgM monoclonal antibody in the rat. The American Journal of Physiology. 1986;250(5 Pt 2):875-883.  https://doi.org/ajpregu.1986.250.5.R875
  3. Neuwelt EA, Specht HD, Hill SA. Permeability of human brain tumor to 99mTc-gluco-heptonate and 99mTc-albumin. Implications for monoclonal antibody therapy. Journal of Neurosurgery. 1986;65(2):194-198.  https://doi.org/10.3171/jns.1986.65.2.0194
  4. Neuwelt EA, Mickey B, Lewy AJ. The importance of melatonin and tumor markers in pineal tumors. Journal of Neural Transmission. Supplementum. 1986;21:397-413. 
  5. Neuwelt EA, Dahlborg SA. Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases. Journal of Neuro-Oncology. 1987;4(3):195-207.  https://doi.org/10.1007/BF00150611
  6. Neuwelt EA, Barnett PA, Hellstrom KE, Hellstrom I, McCormick CI, Ramsey FL. Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. Journal of Nuclear Medicine. 1994;35(11):1831-1841.
  7. Gobin YP, Cloughesy TF, Chow KL, Duckwiler GR, Sayre JW, Milanese K, Viñuela F. Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery. Radiology. 2001;218(3):724-732.  https://doi.org/10.1148/radiology.218.3.r01mr41724
  8. Namba H, Kobayashi S, Iwadate Y, Saegusa T, Sato A, Watanabe Y, Sueyoshi K. Assessment of the brain areas perfused by superselective intra-arterial chemotherapy using single photon emission computed tomography with technetium-99m- hexamethyl-propyleneamine oxime — technical note. Neurologia Medico-Chirurgica. 1994;34(12):832-835.  https://doi.org/10.2176/nmc.34.832
  9. Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma: promise and challenge. Current Pharmaceutical Design. 2007;13(35):3545-3558. https://doi.org/10.2174/138161207782794130
  10. Boockvar JA, Tsiouris AJ, Hofstetter C, Kovanlikaya I, Fralin S, Kesavabhotla K, Seedial SM, Pannullo S, Schwartz TH, Stieg P, Zimmerman RD, Knopman J, Scheff RJ, Christos P, Vallabhajosula S, Riina HA. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Journal of Neurosurgery. 2011;114(3):624-632.  https://doi.org/10.3171/2010.9.JNS101223
  11. Alter RA, White TG, Fanous AA, Chakraborty S, Filippi CG, Pisapia DJ, Tsiouris AJ, Boockvar JA. Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma. Journal of Experimental Therapeutics and Oncology. 2017;12(1):67-71. 
  12. Chakraborty S, Filippi CG, Burkhardt JK, Fralin S, Ray A, Wong T, Ortiz R, Langer DJ, Boockvar JA. Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma. Journal of Experimental Therapeutics and Oncology. 2016;11(4):261-267. 
  13. Singh R, Kesavabhotla K, Kishore SA, Zhou Z, Tsiouris AJ, Filippi CG, Boockvar JA, Kovanlikaya I. Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy. American Journal of Neuroradiology. 2016;37(10):1838-1843. https://doi.org/10.3174/ajnr.A4823
  14. Theodotou C, Shah AH, Hayes S, Bregy A, Johnson JN, Aziz-Sultan MA, Komotar RJ. The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma. British Journal of Neurosurgery. 2014;28(4):438-446.  https://doi.org/10.3109/02688697.2013.877122
  15. Galla N, Chiang G, Chakraborty S, Singh R, Tsiouris AJ, Boockvar J, Kovanlikaya I. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma. Neuroradiology. 2017;59(5):499-505.  https://doi.org/10.1007/s00234-017-1820-4
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.